SK13642001A3 - Farmaceutický prípravok na orálne podávanie obsahujúci tolperizón - Google Patents
Farmaceutický prípravok na orálne podávanie obsahujúci tolperizón Download PDFInfo
- Publication number
- SK13642001A3 SK13642001A3 SK1364-2001A SK13642001A SK13642001A3 SK 13642001 A3 SK13642001 A3 SK 13642001A3 SK 13642001 A SK13642001 A SK 13642001A SK 13642001 A3 SK13642001 A3 SK 13642001A3
- Authority
- SK
- Slovakia
- Prior art keywords
- tolperisone
- isomer
- oral administration
- composition according
- racemate
- Prior art date
Links
- FSKFPVLPFLJRQB-UHFFFAOYSA-N 2-methyl-1-(4-methylphenyl)-3-(1-piperidinyl)-1-propanone Chemical compound C=1C=C(C)C=CC=1C(=O)C(C)CN1CCCCC1 FSKFPVLPFLJRQB-UHFFFAOYSA-N 0.000 title claims abstract description 74
- 239000000825 pharmaceutical preparation Substances 0.000 title claims abstract description 6
- 239000000203 mixture Substances 0.000 claims abstract description 39
- 238000002360 preparation method Methods 0.000 claims abstract description 14
- 150000003839 salts Chemical class 0.000 claims abstract description 13
- 239000004480 active ingredient Substances 0.000 claims abstract description 9
- 230000003111 delayed effect Effects 0.000 claims abstract description 4
- 239000007788 liquid Substances 0.000 claims abstract description 4
- 239000007787 solid Substances 0.000 claims abstract description 4
- 229960005334 tolperisone Drugs 0.000 claims description 68
- 238000009472 formulation Methods 0.000 claims description 12
- 239000013543 active substance Substances 0.000 claims description 8
- 239000008187 granular material Substances 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 210000000936 intestine Anatomy 0.000 claims description 4
- 230000001225 therapeutic effect Effects 0.000 claims 2
- 239000003814 drug Substances 0.000 abstract description 5
- 230000000968 intestinal effect Effects 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 238000000034 method Methods 0.000 description 5
- 239000011230 binding agent Substances 0.000 description 4
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000003094 microcapsule Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 239000001856 Ethyl cellulose Substances 0.000 description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 229920000161 Locust bean gum Polymers 0.000 description 2
- 239000008135 aqueous vehicle Substances 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 235000019325 ethyl cellulose Nutrition 0.000 description 2
- 229920001249 ethyl cellulose Polymers 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000000711 locust bean gum Substances 0.000 description 2
- 235000010420 locust bean gum Nutrition 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 239000000230 xanthan gum Substances 0.000 description 2
- 229920001285 xanthan gum Polymers 0.000 description 2
- 235000010493 xanthan gum Nutrition 0.000 description 2
- 229940082509 xanthan gum Drugs 0.000 description 2
- WCUNKLPJSIFWCQ-UHFFFAOYSA-N 2-methyl-3-(4-methylpiperidin-1-yl)-1-phenylpropan-1-one Chemical compound C=1C=CC=CC=1C(=O)C(C)CN1CCC(C)CC1 WCUNKLPJSIFWCQ-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 206010008334 Cervicobrachial syndrome Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010041415 Spastic paralysis Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 208000018937 joint inflammation Diseases 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 239000003158 myorelaxant agent Substances 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229940045902 sodium stearyl fumarate Drugs 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AT0059499A AT409083B (de) | 1999-04-01 | 1999-04-01 | Pharmazeutische, tolperison enthaltende zubereitung zur oralen verabreichung |
| PCT/AT1999/000276 WO2000059508A1 (de) | 1999-04-01 | 1999-11-16 | Tolperison enthaltende, pharmazeutische zubereitung zur oralen verabreichung |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SK13642001A3 true SK13642001A3 (sk) | 2002-03-05 |
Family
ID=3494723
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SK1364-2001A SK13642001A3 (sk) | 1999-04-01 | 1999-11-16 | Farmaceutický prípravok na orálne podávanie obsahujúci tolperizón |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US6500455B1 (https=) |
| EP (1) | EP1165081B1 (https=) |
| JP (1) | JP2002541107A (https=) |
| AT (1) | AT409083B (https=) |
| AU (1) | AU1136400A (https=) |
| CA (1) | CA2366841C (https=) |
| CZ (1) | CZ20013404A3 (https=) |
| DE (1) | DE59912101D1 (https=) |
| EE (1) | EE04833B1 (https=) |
| ES (1) | ES2168241T3 (https=) |
| HR (1) | HRPK20010706B1 (https=) |
| HU (1) | HUP0200669A3 (https=) |
| IL (2) | IL145559A0 (https=) |
| NO (1) | NO20014738L (https=) |
| NZ (1) | NZ514129A (https=) |
| PL (1) | PL197545B1 (https=) |
| PT (1) | PT1165081E (https=) |
| RU (1) | RU2223098C2 (https=) |
| SK (1) | SK13642001A3 (https=) |
| TR (1) | TR200102811T2 (https=) |
| UA (1) | UA71613C2 (https=) |
| WO (1) | WO2000059508A1 (https=) |
| YU (1) | YU67501A (https=) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUP0300929A3 (en) * | 2003-04-09 | 2005-06-28 | Richter Gedeon Vegyeszet | Analgetic and/or muscle relaxant pharmaceutical composition |
| DE10341923A1 (de) * | 2003-09-11 | 2005-04-07 | Heinl, Alexander, Dr.med. | Verwendung von Tolperison |
| US20050089559A1 (en) * | 2003-10-23 | 2005-04-28 | Istvan Szelenyi | Combinations of potassium channel openers and sodium channel inhibitors or sodium channel-influencing active compounds for treating pains |
| DE10359335A1 (de) * | 2003-10-23 | 2005-05-25 | Viatris Gmbh & Co. Kg | Kombinationen aus Kaliumkanalöffnern und Natriumkanalinhibitoren oder Natriumkanal beeinflussenden Wirkstoffen zur Behandlung von Schmerzzuständen |
| AT500144A1 (de) * | 2004-03-05 | 2005-11-15 | Sanochemia Pharmazeutika Ag | Tolperison enthaltende, pharmazeutische zubereitung mit steuerbarer wirkstofffreisetzung zur oralen verabreichung |
| MX2008013437A (es) * | 2006-04-20 | 2009-03-06 | Sanochemia Pharmazeutika Ag | Metodo para administrar tolperisona. |
| US7960436B2 (en) | 2006-06-05 | 2011-06-14 | Valeant Pharmaceuticals International | Substituted arylamino-1,2,3,4-tetrahydro naphthalenes and-2,3-dihydro-1H-indenes as potassium channel modulators |
| US8993593B2 (en) * | 2006-08-23 | 2015-03-31 | Valeant Pharmaceuticals International | N-(4-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-2,6-dimethylphenyl)-3,3-dimethylbutanamide as potassium channel modulators |
| BRPI0716715B1 (pt) | 2006-08-23 | 2021-07-06 | Xenon Pharmaceuticals, Inc | Derivados de 4-(n-azacicloalquil) anilidas como moduladores de canal de potássio, seus usos, produto, composição, comprimido e cápsula |
| US8722929B2 (en) | 2006-10-10 | 2014-05-13 | Valeant Pharmaceuticals International | N-[2-amino-4-(phenylmethoxy)phenyl] amides and related compounds as potassium channel modulators |
| CA2670966A1 (en) * | 2006-11-28 | 2008-06-05 | Valeant Pharmaceuticals International | 1,4 diamino bicyclic retigabine analogues as potassium channel modulators |
| AT505225A1 (de) | 2007-04-26 | 2008-11-15 | Sanochemia Pharmazeutika Ag | 0erfahren zur herstellung von hoch reinem 2,4'-dimethyl-3-piperidino-propiophenon (tolperison), dieses enthaltende pharmazeutische zusammensetzungen, sowie tolperison enthaltende wirkstoffformulierungen |
| US8367684B2 (en) | 2007-06-13 | 2013-02-05 | Valeant Pharmaceuticals International | Derivatives of 4-(N-azacycloalkyl) anilides as potassium channel modulators |
| HUP0700485A3 (en) * | 2007-07-23 | 2010-01-28 | Richter Gedeon Nyrt | Pharmaceutical composition with controlled release containing tolperisone |
| US8563566B2 (en) | 2007-08-01 | 2013-10-22 | Valeant Pharmaceuticals International | Naphthyridine derivatives as potassium channel modulators |
| US7786146B2 (en) | 2007-08-13 | 2010-08-31 | Valeant Pharmaceuticals International | Derivatives of 5-amino-4,6-disubstituted indole and 5-amino-4,6-disubstituted indoline as potassium channel modulators |
| US8865732B2 (en) | 2008-03-21 | 2014-10-21 | Novartis Ag | Heterocyclic compounds and uses thereof |
| US20100249423A1 (en) * | 2009-03-09 | 2010-09-30 | Sanochemia Pharmazeutika Ag | Tolperisone controlled release tablet |
| EA201171109A1 (ru) | 2009-03-09 | 2012-03-30 | Динеш Шантилал Пател | Новая композиция замедленного высвобождения соединений, выбранных из класса миорелаксантов центрального действия |
| TWI886158B (zh) | 2019-10-10 | 2025-06-11 | 加拿大商再諾製藥公司 | 選擇性鉀通道調節劑之固態晶型 |
| WO2021092439A1 (en) | 2019-11-08 | 2021-05-14 | Xenon Pharmaceuticals Inc. | Methods of treating depressive disorders |
| IL304920A (en) | 2021-02-09 | 2023-10-01 | Xenon Pharmaceuticals Inc | A voltage-gated potassium channel opener for use in the treatment of anhedonia |
| USD1109826S1 (en) | 2024-02-16 | 2026-01-20 | Coulter Ventures, Llc. | Weightlifting assembly |
| WO2026074301A1 (en) | 2024-10-02 | 2026-04-09 | Meditop Gyógyszeripari Kft | Sustained release oral medicinal product containing tolperisone hydrochloride, its production and use |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5154918A (en) * | 1974-10-08 | 1976-05-14 | Nippon Kayaku Kk | Jozaino seizoho |
| JPS5191315A (ja) * | 1975-02-06 | 1976-08-10 | Anteinaensantoruperizonshirotsupunoseizoho | |
| JPS5340779A (en) * | 1976-09-21 | 1978-04-13 | Nippon Kayaku Co Ltd | Optically active tolpertisone, their preparation and pharmaceuticals containting the same |
| JPS58135806A (ja) * | 1982-02-08 | 1983-08-12 | Nippon Kayaku Co Ltd | 多層コ−チング製剤 |
| JPS6143108A (ja) * | 1984-08-03 | 1986-03-01 | Nippon Shinyaku Co Ltd | 医薬品製剤及びその製造法 |
| JPH0637389B2 (ja) * | 1986-12-26 | 1994-05-18 | 北陸製薬株式会社 | 頻尿治療剤 |
| JPH0720866B2 (ja) | 1987-05-15 | 1995-03-08 | 三生製薬株式会社 | エペリゾン又はトルペリゾン或いはそれらの塩類含有経皮適用製剤 |
| IL87710A (en) | 1987-09-18 | 1992-06-21 | Ciba Geigy Ag | Covered floating retard form for controlled release in gastric juice |
| MY115126A (en) * | 1990-04-27 | 2003-04-30 | Seikisui Chemical Co Ltd | Percutaneously absorbable eperisone or tolperisone preparation. |
| US5128145A (en) * | 1990-06-13 | 1992-07-07 | Alza Corporation | Dosage form for Parkinson's disease, spasticity and muscle spasms |
| TW209174B (https=) * | 1991-04-19 | 1993-07-11 | Takeda Pharm Industry Co Ltd | |
| ATE154241T1 (de) * | 1991-10-01 | 1997-06-15 | Takeda Chemical Industries Ltd | Mikropartikeln-zusammenfassung zur verlängerten freigabe und herstellung derselbe |
| US5811547A (en) * | 1992-10-14 | 1998-09-22 | Nippon Shinyaju Co., Ltd. | Method for inducing crystalline state transition in medicinal substance |
| GB9319606D0 (en) * | 1993-09-22 | 1993-11-10 | Glaxo Group Ltd | Chemical compounds |
-
1999
- 1999-04-01 AT AT0059499A patent/AT409083B/de not_active IP Right Cessation
- 1999-11-16 RU RU2001129368/15A patent/RU2223098C2/ru not_active IP Right Cessation
- 1999-11-16 PT PT99973809T patent/PT1165081E/pt unknown
- 1999-11-16 IL IL14555999A patent/IL145559A0/xx unknown
- 1999-11-16 CA CA002366841A patent/CA2366841C/en not_active Expired - Fee Related
- 1999-11-16 HU HU0200669A patent/HUP0200669A3/hu unknown
- 1999-11-16 JP JP2000609071A patent/JP2002541107A/ja not_active Withdrawn
- 1999-11-16 ES ES99973809T patent/ES2168241T3/es not_active Expired - Lifetime
- 1999-11-16 YU YU67501A patent/YU67501A/sh unknown
- 1999-11-16 US US09/937,710 patent/US6500455B1/en not_active Expired - Lifetime
- 1999-11-16 EP EP99973809A patent/EP1165081B1/de not_active Expired - Lifetime
- 1999-11-16 DE DE59912101T patent/DE59912101D1/de not_active Expired - Fee Related
- 1999-11-16 EE EEP200100503A patent/EE04833B1/xx not_active IP Right Cessation
- 1999-11-16 TR TR2001/02811T patent/TR200102811T2/xx unknown
- 1999-11-16 SK SK1364-2001A patent/SK13642001A3/sk unknown
- 1999-11-16 NZ NZ514129A patent/NZ514129A/xx unknown
- 1999-11-16 WO PCT/AT1999/000276 patent/WO2000059508A1/de not_active Ceased
- 1999-11-16 PL PL351377A patent/PL197545B1/pl not_active IP Right Cessation
- 1999-11-16 CZ CZ20013404A patent/CZ20013404A3/cs unknown
- 1999-11-16 UA UA2001117476A patent/UA71613C2/uk unknown
- 1999-11-16 HR HR20010706 patent/HRPK20010706B1/xx not_active IP Right Cessation
- 1999-11-18 AU AU11364/00A patent/AU1136400A/en not_active Abandoned
-
2001
- 2001-09-23 IL IL145559A patent/IL145559A/en not_active IP Right Cessation
- 2001-09-28 NO NO20014738A patent/NO20014738L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2000059508A1 (de) | 2000-10-12 |
| CZ20013404A3 (cs) | 2002-02-13 |
| AU1136400A (en) | 2000-10-23 |
| HUP0200669A3 (en) | 2002-11-28 |
| IL145559A0 (en) | 2002-06-30 |
| EE200100503A (et) | 2003-02-17 |
| ES2168241T1 (es) | 2002-06-16 |
| UA71613C2 (uk) | 2004-12-15 |
| PT1165081E (pt) | 2005-08-31 |
| HRPK20010706B1 (en) | 2004-12-31 |
| NO20014738D0 (no) | 2001-09-28 |
| RU2223098C2 (ru) | 2004-02-10 |
| PL197545B1 (pl) | 2008-04-30 |
| CA2366841A1 (en) | 2000-10-12 |
| EP1165081B1 (de) | 2005-05-25 |
| EE04833B1 (et) | 2007-06-15 |
| NO20014738L (no) | 2001-10-23 |
| JP2002541107A (ja) | 2002-12-03 |
| AT409083B (de) | 2002-05-27 |
| HRP20010706A2 (en) | 2003-02-28 |
| IL145559A (en) | 2008-12-29 |
| ATA59499A (de) | 2001-10-15 |
| YU67501A (sh) | 2004-07-15 |
| TR200102811T2 (tr) | 2002-05-21 |
| CA2366841C (en) | 2008-10-07 |
| DE59912101D1 (de) | 2005-06-30 |
| US6500455B1 (en) | 2002-12-31 |
| EP1165081A1 (de) | 2002-01-02 |
| HUP0200669A2 (hu) | 2002-07-29 |
| PL351377A1 (en) | 2003-04-07 |
| ES2168241T3 (es) | 2005-11-01 |
| NZ514129A (en) | 2003-04-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SK13642001A3 (sk) | Farmaceutický prípravok na orálne podávanie obsahujúci tolperizón | |
| FI82187B (fi) | Foerfarande foer framstaellning av lagerstabila snabbsoenderfallande farmaceutiska aktivaemnespresstycken. | |
| AU603624B2 (en) | Galenical formulation | |
| US4784858A (en) | Controlled release tablet | |
| AU760006B2 (en) | Method for making granules with masked taste and instant release of the active particle | |
| US5211958A (en) | Pharmaceutical composition and process for its preparation | |
| BG64885B1 (bg) | Фармацевтичен състав на топирамат | |
| AU2010211980A1 (en) | Dual release pharmaceutical suspension | |
| EA014707B1 (ru) | Новая форма введения рацекадотрила | |
| SK8252001A3 (en) | Controlled release formulation of divalproex sodium | |
| WO2009074995A1 (en) | Taste masked chewable compositions of sildenafil citrate | |
| EP1673064A1 (en) | Pharmaceutical composition comprising anticonvulsant with taste mask coating | |
| JP3836893B2 (ja) | ポリカルボフィルカルシウム含有製剤 | |
| CA1334933C (en) | Pharmaceutical composition and process for its preparation | |
| KR20010114227A (ko) | 직접 압착에 의한 정제의 제조에 적합한, 고 함량의ｌ-카르니틴 또는 알카노일 ｌ-카르니틴 함유 과립 | |
| US20090149543A1 (en) | Solid pharmaceutical compositions comprising lumiracoxib | |
| WO2009130715A1 (en) | Rapidly disintegrating oral compositions of tramadol | |
| HUE029193T2 (en) | Delayed release drug formulations of thiocolchicoside |